Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy

Plain-language summary

This study evaluates the risk of developing myelodysplastic syndrome in patients who have received or are planned to receive peptide receptor radionuclide therapy (PRRT) for a neuroendocrine tumor (NET). It enrolls patients who have completed or are planned for PRRT, or who developed MDS/AML after such therapy. It is a study with no assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

University Health Network, Toronto

Intervention

Peptide receptor radionuclide therapy (PRRT), Blood collection

Start date

8/1/2024

Estimated completion

6/30/2029

Countries

Canada

Related genes

Locations

• Toronto, Canada

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* ECOG 0-3
* Life expectancy \> 6 months
* Informed consent and willingness to undergoing serial genetic panel CHIP testing.
* Cohort Specific criteria

  1. Cohort A: PRRT completed within 5 years of enrolment
  2. Cohort B: PRRT planned to commence within 4 months of enrolment
  3. Cohort C: diagnosis of MDS or AML following prior PRRT.

     Exclusion Criteria:
* Unwillingness to provide blood sample and follow up as per protocol